New drug duo aims to hold back deadly pancreatic cancer
NCT ID NCT04666740
Summary
This study is testing whether combining two drugs, pembrolizumab and olaparib, can better control advanced pancreatic cancer that has spread. The treatment is for patients whose cancer has stopped growing or shrunk while on platinum-based chemotherapy. Researchers want to see if this combination can keep the cancer from progressing longer than using olaparib alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Basking Ridge (All protocol activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Bergen (All protocol activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (All protocol activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (All protocol activities)
Rockville Centre, New York, 11553, United States
-
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, 10604, United States
Conditions
Explore the condition pages connected to this study.